This new patent letter of allowance received from the USPTO further expands the Company's intellectual property estate intended for treating, suppressing and preventing cancer tumor formation and progression.
Leonhardt Ventures LLC and its cancer treating and research subsidiary CancerCell LTP www.cancercellinc..com now has 12 issued or exclusively licensed patents covering bioelectric cancer treatment. The company believes bioelectric cancer treatments have the potential to be a less toxic and less expensive alternative for many patients and is undertaking studies to prove out the safety and efficacy of this approach. Links to previously issued bioelectric cancer treatment patents may be found here https://cancercellinc.com/list-of-the-issued-cancer-patents/ and here https://patents.justia.com/inventor/howard-j-leonhardt
Mission Viejo, CA , March 2nd, 2023 /PRdistribution/ – Leonhardt Ventures LLC, a leading medtech innovation firm, and its subsidiary CancerCell, announced today receipt of a Letter of Allowance issuing 12 new patent claims.
The new U.S. issued patent will broadly cover methods, bioelectric signaling software and apparatus used to treat blood and bone related cancers. Specifically bioelectric signaling to control release of osteoprotegerin (OPG) to prevent bone degradation especially in multiple myeloma patients.
Summary: A bioelectric stimulator programmed to produce at least one bioelectric signal that stimulate(s) target tissue of a subject to increase expression of osteoprotegerin (OPG), thus inhibiting bone degradation in the subject
“My mother Penny passed away from multiple myeloma at age 49. She would have been 78 this coming March 9th. So this patent issuance is special to me personally. I saw how my Mom’s bones became to look like Swiss cheese with bone degradation holes that ruined her quality of life in her last years. We hope this technology prevents this in new patients suffering of this terrible form of cancer” stated Howard J. Leonhardt, Inventor and Executive Chairman Leonhardt Ventures LLC and CancerCell LTP
Myeloma cells express RANKL and cause bone marrow residing stromal cells to overexpress RANKL. In addition, myeloma cells inhibit OPG production by stromal cells The physiologic balance between RANKL and OPG is tilted by these combined effects, and the ensuing enhanced RANKL-to-OPG ratio promotes osteoclast formation and activation, which is responsible for rapid bone loss, fractures, pain and worsening spread of the cancer. OPG counteracts the action of RANKL osteoclasts and thus stops bone degradation and may even reverse the cancer action of cells.
BM biopsy specimens from multiple myeloma (MM) patients show increased RANKL expression and decreased OPG expression in BMSCs. Co-cultures of MM cells induced RANKL mRNA expression and suppressed OPG mRNA expression in BMSCs. Therefore, MM cells are suggested to dysregulate the RANKL/RANK/OPG system to enhance RANKL action in the MM BM microenvironment. Indeed, blocking RANKL with recombinant OPG or RANK-Fc significantly reduced osteolytic lesions and tumor expansion, See reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477206/?fbclid=IwAR2WGRf986B0w7vCKSOXJnRYyRxW3OcQWM_iixlqr5K4KN8GSZhMzawXxig
Working in partnership with BodStim www.bodstim.com the CancerCell and Leonhardt Ventures LLC research teams with the support of Leonhardt's Launchpads Brazil is preparing to launch a first in man study for suppressing cancer tumor progression next quarter. Details will be shared shortly.
About Leonhardt Ventures LLC:
Since 1982 Leonhardt Ventures LLC has been a leader in medtech and biotech innovation. See www.leonhardtventures.com for more information.
About CancerCell LTP:
CancerCell LTP is an early stage startup in the Leonhardt’s Launchpads incubator and Cal-X Stars Business Accelerator, Inc. accelerator programs focused on bioelectric and biologics treatments for cancer. See www.cancercellinc.com
Director of Marketing
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including, without limitation, statements as to our ability to improve the management and treatment of cancer and to complete planned clinical studies. Such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors and potential delays, including regulatory delays, as set forth in published Annual Reports, effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our Annual Report and Private Placement Memorandum for associated risks.